高级检索
    梁汉霖, 王羽, 谢德荣. 关于晚期胰腺癌的Meta分析:吉西他滨联合化疗与吉西他滨单药[J]. 循证医学, 2005, 5(3): 156-165. DOI: 10.3969/j.issn.1671-5144.2005.03.008
    引用本文: 梁汉霖, 王羽, 谢德荣. 关于晚期胰腺癌的Meta分析:吉西他滨联合化疗与吉西他滨单药[J]. 循证医学, 2005, 5(3): 156-165. DOI: 10.3969/j.issn.1671-5144.2005.03.008
    shu
    LIANG Han-lin, WANG Yu, XIE De-rong. Comparing Gemcitabine-based Combination Chemotherapy with Gemcitabine Alone in Inoperable Pancreatic Cancer: A Meta-analysis[J]. Journal of Evidence-Based Medicine, 2005, 5(3): 156-165. DOI: 10.3969/j.issn.1671-5144.2005.03.008
    Citation: LIANG Han-lin, WANG Yu, XIE De-rong. Comparing Gemcitabine-based Combination Chemotherapy with Gemcitabine Alone in Inoperable Pancreatic Cancer: A Meta-analysis[J]. Journal of Evidence-Based Medicine, 2005, 5(3): 156-165. DOI: 10.3969/j.issn.1671-5144.2005.03.008
    shu

    关于晚期胰腺癌的Meta分析:吉西他滨联合化疗与吉西他滨单药

    Comparing Gemcitabine-based Combination Chemotherapy with Gemcitabine Alone in Inoperable Pancreatic Cancer: A Meta-analysis

      摘要
    • 摘要: 目的通过Meta分析,探讨吉西他滨联合化疗和吉西他滨单药化疗在治疗晚期胰腺癌病人中的意义.方法通过MEDLINE、EMBASE、ASCO论文集等数据库检索国内外已发表和未发表的相关文献.选择治疗组为吉西他滨联合化疗,对照组为吉西他滨单药化疗的晚期胰腺癌的随机对照试验.由2位评价者分别收集资料,按纳入标准入选,主要对总生存率进行Meta分析,其次是客观缓解率、临床受益率、肿瘤进展时间/无进展生存、毒副反应.结果共纳入19个随机对照试验.在治疗晚期胰腺癌方面,吉西他滨联合化疗与吉西他滨单药化疗比较,半年生存率

       

      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回